ArticleDiscover oncology2023
Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance.
Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Smoking promotes colorectal cancer via the CKAP2L/AREG axis.International journal of oncology · 2026Article
- Article
- Identification of senescence-related genes as diagnostic biomarkers for gastric cancer using bioinformatics and machine learning.Discover oncology · 2026Article
- BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability.Cell death discovery · 2026Article
- Renal cell carcinoma presenting with orbital metastasis as the initial symptom: A case report.Medicine · 2026Article
- Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.Discover oncology · 2026Article
- Bellidifolin mitigates doxorubicin-induced myocardial injury via regulating oxidative stress, inflammation, and apoptosis: a combination of network pharmacology and experiments.Journal of molecular histology · 2026Article
- PRDM1: a useful indicator of differentiation and prognosis in esophageal squamous cell carcinoma.Diagnostic pathology · 2026Article
- Cepharanthine alleviated chronic prostatitis/chronic pelvic pain syndrome by activating Nrf2 and inhibiting the NF-κB pathway.Biology direct · 2026Article
- Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway.Scientific reports · 2026Article
- DMBX1 expression in colon cancer and its impact on prognosis and the tumor microenvironment.BMC medical genomics · 2026Article
- Systematic pan-cancer analysis identifies PIK3R3 as a lipid metabolism and immune regulation prognostic biomarker.Open medicine (Warsaw, Poland) · 2026Article
- Deciphering the Role of Long Non-coding RNAs in Neural Differentiation and Reprogramming.Stem cell reviews and reports · 2025Review
- Differential response of patient-derived primary glioblastoma cells to metabolic and adhesion inhibitors.Clinical and experimental medicine · 2025Article
- Curcumin ameliorates heatstroke-induced lung injury by activating the PI3K/AKT pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Pan‑immune‑inflammatory values predict survival in patients after radical surgery for non‑metastatic colorectal cancer: A retrospective study.Oncology letters · 2025Article
- Cancer-Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple-Negative Breast Cancer via the Activation of Cancer-Associated Fibroblasts.Global challenges (Hoboken, NJ) · 2025Article
- Machine learning-driven SLC prognostic signature for glioma: predicting survival and immunotherapy response.Frontiers in pharmacology · 2025Article
- Human annexin A5 promotes glioma progression by targeting theFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundGlioma is a lethal brain cancer and lacking effective therapies. Challenges include no effective therapeutic target, intra- and intertumoral heterogeneity, inadequate effective drugs, and an immunosuppressive microenvironment, etc. Deciphering the pathogenesis of gliomas and finding out the working mechanisms are urgent and necessary for glioma treatment. Identification of prognostic biomarkers and targeting the biomarker genes will be a promising therapy.
methodsFrom our RNA-sequencing data of the oxidative phosphorylation (OXPHOS)-inhibition sensitive and OXPHOS-resistant cell lines, we found that the scaffolding protein caveolin 1 (CAV1) is highly expressed in the resistant group but not in the sensitive group. By comprehensive analysis of our RNA sequencing data, Whole Genome Bisulfite Sequencing (WGBS) data and public databases, we found that CAV1 is highly expressed in gliomas and its expression is positively related with pathological processes, higher CAV1 predicts shorter overall survival.
resultsFurther analysis indicated that (1) the differentiated genes in CAV1-high groups are enriched in immune infiltration and immune response; (2) CAV1 is positively correlated with tumor metastasis markers; (3) the methylation level of CAV1 promoters in glioma group is lower in higher stage than that in lower stage; (4) CAV1 is positively correlated with glioma stemness; (5) higher expression of CAV1 renders the glioma cells' resistant to oxidative phosphorylation inhibitors.
conclusionTherefore, we identified a key gene CAV1 and deciphered its function in glioma progression and prognosis, proposing that CAV1 may be a therapeutic target for gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.